SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage
Biosciences, a cancer biotechnology company pioneering a new cancer
drug development approach using its CIVO™ multiplexed
intratumoral microdosing platform, today announced it has entered
into a research collaboration with Bristol-Myers Squibb Company
(NYSE: BMY) to evaluate early stage oncology targets in Phase 0
trials. Presage's CIVO platform is used to evaluate patients'
unique responses to microdoses of multiple cancer drugs.
"We are pleased to announce another collaboration to expand the
use of CIVO technology in Phase 0 trials," said Rich Klinghoffer, PhD, Presage CEO. "With CIVO
we are able to directly evaluate responses to multiple drugs and
combinations within a single tumor, providing a wealth of
information much earlier in the drug development process with a
goal to help reduce risk and accelerate the drug development
timeline."
At Bristol-Myers Squibb we are seeking a more precise
understanding of how treatments impact each patient to help inform
tailored therapeutic strategies that will offer the greatest
possible benefit," said Jonathan
Leith, Head, Clinical Mechanisms at Bristol-Myers Squibb.
"This collaboration may provide important insights about how our
compounds work mechanistically in combination studies and help us
bring forward more effective options for patients with cancer."
This is the third program Presage has partnered to utilize the
innovative CIVO platform to investigate tumor cell and
microenvironment responses to investigational agents in a Phase 0
clinical trial.
Specific terms and details regarding the collaboration are
undisclosed.
About CIVO and Phase 0 Trials
To address the
challenges inherent in cancer drug discovery, Presage is advancing
a new approach to rapidly evaluate multiple drug candidates and
enhance knowledge applicable for future trial design. Exploratory
Investigational New Drug studies, also known as Phase 0 trials,
allow for the evaluation of minute amounts of drugs in patients to
assess pharmacodynamic effects. CIVO is a patented platform that
enables intratumoral microdosing and analysis of multiple cancer
agents.
About Presage
Presage Biosciences is an oncology
company pioneering a new drug development approach to assess novel
therapeutics and combinations directly in human tumors with its
patented CIVO™ intratumoral microdosing platform. The CIVO platform
is intended to enable simultaneous assessment of responses to
multiple drugs or drug combinations directly in a single tumor
while still in a patient's body. Presage also partners with
oncology-focused pharmaceutical companies through strategic
alliances to provide preclinical data to discover effective drug
combinations. Presage is privately held and based in Seattle. For more information, visit
www.presagebio.com.
Media Contact:
Julie
Rathbun
Rathbun Communications
(206) 769-9219
Julie@rathbuncomm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/presage-announces-collaboration-with-bristol-myers-squibb-for-phase-o-studies-of-novel-cancer-agents-utilizing-civo-technology-300907381.html
SOURCE Presage Biosciences